it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
.
.
richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine.
.
.
.
.